Tag: SpringWorks Therapeutics

Merck KGaA's recent $3.9 billion acquisition of SpringWorks Therapeutics is demonstrating immediate strategic value, with European regulators granting marketing authorization ...

SpringWorks Therapeutics has achieved a significant regulatory milestone with the European Commission granting marketing authorization for its therapy, Nirogacestat (Ogsiveo). ...